CA2931144C - Anti-infective methods, compositions, and devices - Google Patents
Anti-infective methods, compositions, and devices Download PDFInfo
- Publication number
- CA2931144C CA2931144C CA2931144A CA2931144A CA2931144C CA 2931144 C CA2931144 C CA 2931144C CA 2931144 A CA2931144 A CA 2931144A CA 2931144 A CA2931144 A CA 2931144A CA 2931144 C CA2931144 C CA 2931144C
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- efinaconazole
- treatment
- nail
- treatment area
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 372
- 238000000034 method Methods 0.000 title abstract description 198
- 230000002924 anti-infective effect Effects 0.000 title description 2
- NFEZZTICAUWDHU-RDTXWAMCSA-N efinaconazole Chemical compound N1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)CCC(=C)CC1 NFEZZTICAUWDHU-RDTXWAMCSA-N 0.000 claims abstract description 381
- 229960003937 efinaconazole Drugs 0.000 claims abstract description 331
- 238000009472 formulation Methods 0.000 claims abstract description 300
- 238000011282 treatment Methods 0.000 claims abstract description 295
- 208000010195 Onychomycosis Diseases 0.000 claims abstract description 115
- 201000005882 tinea unguium Diseases 0.000 claims abstract description 115
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 65
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims abstract description 47
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims abstract description 47
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims abstract description 47
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims abstract description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- -1 C12-15 alkyl lactate Substances 0.000 claims abstract description 16
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims abstract description 15
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940031578 diisopropyl adipate Drugs 0.000 claims abstract description 14
- 229940026215 c12-15 alkyl lactate Drugs 0.000 claims abstract description 13
- 229940086555 cyclomethicone Drugs 0.000 claims abstract description 13
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract 8
- 238000004140 cleaning Methods 0.000 claims description 19
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 238000003860 storage Methods 0.000 claims description 7
- 238000004891 communication Methods 0.000 claims description 6
- 238000005520 cutting process Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000009736 wetting Methods 0.000 claims description 4
- 210000000282 nail Anatomy 0.000 description 138
- 210000004906 toe nail Anatomy 0.000 description 67
- 239000003981 vehicle Substances 0.000 description 54
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 51
- 239000003814 drug Substances 0.000 description 28
- 210000001255 hallux Anatomy 0.000 description 26
- 229940079593 drug Drugs 0.000 description 25
- 230000002354 daily effect Effects 0.000 description 21
- 238000011068 loading method Methods 0.000 description 21
- 229920001296 polysiloxane Polymers 0.000 description 21
- 210000003371 toe Anatomy 0.000 description 20
- 239000002207 metabolite Substances 0.000 description 17
- 230000036470 plasma concentration Effects 0.000 description 17
- 229960004106 citric acid Drugs 0.000 description 16
- 239000000463 material Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000003892 spreading Methods 0.000 description 15
- 230000007480 spreading Effects 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 14
- 238000001804 debridement Methods 0.000 description 14
- 210000002683 foot Anatomy 0.000 description 12
- 210000000454 fifth toe Anatomy 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000009885 systemic effect Effects 0.000 description 10
- 230000000699 topical effect Effects 0.000 description 10
- 238000011269 treatment regimen Methods 0.000 description 10
- 230000002411 adverse Effects 0.000 description 9
- 230000035515 penetration Effects 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000004922 lacquer Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 239000000080 wetting agent Substances 0.000 description 8
- 240000001624 Espostoa lanata Species 0.000 description 7
- 235000009161 Espostoa lanata Nutrition 0.000 description 7
- 210000004905 finger nail Anatomy 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 241001480043 Arthrodermataceae Species 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 230000037304 dermatophytes Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229960001484 edetic acid Drugs 0.000 description 6
- 229960004756 ethanol Drugs 0.000 description 6
- 210000004904 fingernail bed Anatomy 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 206010040914 Skin reaction Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 229960003749 ciclopirox Drugs 0.000 description 5
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 230000004907 flux Effects 0.000 description 5
- 210000000455 fourth toe Anatomy 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 210000000453 second toe Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 4
- 206010003036 Application site dermatitis Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229920002678 cellulose Chemical class 0.000 description 4
- 239000001913 cellulose Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000009969 flowable effect Effects 0.000 description 4
- 238000004362 fungal culture Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000036562 nail growth Effects 0.000 description 4
- 230000000149 penetrating effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000000431 third toe Anatomy 0.000 description 4
- 206010048941 Application site vesicles Diseases 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 102000018832 Cytochromes Human genes 0.000 description 3
- 108010052832 Cytochromes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 230000008406 drug-drug interaction Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000009827 uniform distribution Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000019300 CLIPPERS Diseases 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 2
- 102000002269 Cytochrome P-450 CYP2C9 Human genes 0.000 description 2
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 2
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 238000011374 additional therapy Methods 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940124274 edetate disodium Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000026721 nail disease Diseases 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000565 sealant Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 2
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- CDNNKGWZSNSADW-UHFFFAOYSA-N 2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16,18,18,20,20-icosamethyl-1,3,5,7,9,11,13,15,17,19-decaoxa-2,4,6,8,10,12,14,16,18,20-decasilacycloicosane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 CDNNKGWZSNSADW-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 description 1
- YEOVWCQMQZOEOE-UHFFFAOYSA-N 2-decyl-2-methyl-1,3,5,7,9,2,4,6,8,10-pentaoxapentasilecane Chemical compound CCCCCCCCCC[Si]1(C)O[SiH2]O[SiH2]O[SiH2]O[SiH2]O1 YEOVWCQMQZOEOE-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 101000999655 Colwellia maris Isocitrate dehydrogenase [NADP] 1 Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 101000960235 Dictyostelium discoideum Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 231100000264 OECD 451 Carcinogenicity Study Toxicity 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000825258 Scopulariopsis brevicaulis Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 241001480048 Trichophyton tonsurans Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940085237 carbomer-980 Drugs 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 231100000505 clastogenic Toxicity 0.000 description 1
- 230000003541 clastogenic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940049657 cyclomethicone 5 Drugs 0.000 description 1
- DDJSWKLBKSLAAZ-UHFFFAOYSA-N cyclotetrasiloxane Chemical compound O1[SiH2]O[SiH2]O[SiH2]O[SiH2]1 DDJSWKLBKSLAAZ-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000008686 ergosterol biosynthesis Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000009248 fertility and early embryonic development Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 208000033511 fungal infection of the toenail Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- VHVPQPYKVGDNFY-ZPGVKDDISA-N itraconazole Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-ZPGVKDDISA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940089474 lamisil Drugs 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 230000037383 nail absorption Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 229940087656 penlac nail lacquer Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004800 psychological effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 238000009528 vital sign measurement Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T83/00—Cutting
- Y10T83/04—Processes
- Y10T83/0405—With preparatory or simultaneous ancillary treatment of work
- Y10T83/0443—By fluid application
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3052643A CA3052643A1 (en) | 2013-11-22 | 2014-11-24 | Anti-infective methods, compositions, and devices |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907401P | 2013-11-22 | 2013-11-22 | |
| US61/907,401 | 2013-11-22 | ||
| PCT/US2014/067184 WO2015077729A2 (en) | 2013-11-22 | 2014-11-24 | Anti-infective methods, compositions, and devices |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3052643A Division CA3052643A1 (en) | 2013-11-22 | 2014-11-24 | Anti-infective methods, compositions, and devices |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2931144A1 CA2931144A1 (en) | 2015-05-28 |
| CA2931144C true CA2931144C (en) | 2020-02-04 |
Family
ID=53180413
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2931144A Active CA2931144C (en) | 2013-11-22 | 2014-11-24 | Anti-infective methods, compositions, and devices |
| CA3052643A Abandoned CA3052643A1 (en) | 2013-11-22 | 2014-11-24 | Anti-infective methods, compositions, and devices |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3052643A Abandoned CA3052643A1 (en) | 2013-11-22 | 2014-11-24 | Anti-infective methods, compositions, and devices |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10245257B2 (enExample) |
| EP (1) | EP3071295A4 (enExample) |
| JP (2) | JP6611014B2 (enExample) |
| KR (2) | KR20160087898A (enExample) |
| CN (2) | CN112999223A (enExample) |
| CA (2) | CA2931144C (enExample) |
| WO (1) | WO2015077729A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090175810A1 (en) | 2008-01-03 | 2009-07-09 | Gareth Winckle | Compositions and methods for treating diseases of the nail |
| US8039494B1 (en) | 2010-07-08 | 2011-10-18 | Dow Pharmaceutical Sciences, Inc. | Compositions and methods for treating diseases of the nail |
| US9662394B2 (en) | 2013-10-03 | 2017-05-30 | Dow Pharmaceutical Sciences, Inc. | Stabilized efinaconazole compositions |
| CN112999223A (zh) * | 2013-11-22 | 2021-06-22 | 博世健康爱尔兰有限公司 | 抗感染的方法、组合物和装置 |
| CN106918672B (zh) * | 2015-12-28 | 2021-02-09 | 中美华世通生物医药科技（武汉）有限公司 | 利用hplc测定艾氟康唑原料药及其制剂中有关物质的方法 |
| WO2019088005A1 (ja) * | 2017-10-30 | 2019-05-09 | 科研製薬株式会社 | 爪白癬治療用の外用製剤 |
| WO2019240212A1 (ja) * | 2018-06-14 | 2019-12-19 | 株式会社カネカ | 薬学的活性成分を含む製剤 |
| KR102060546B1 (ko) * | 2019-06-07 | 2019-12-30 | 주식회사 바이오빌리프 | 에피나코나졸을 함유하는 용액 형태의 국소 투여용 약학 조성물 |
| WO2021054531A2 (ko) * | 2019-09-17 | 2021-03-25 | 주식회사 바이오빌리프 | 항산화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물 |
| WO2021054535A2 (ko) * | 2019-09-17 | 2021-03-25 | 주식회사 바이오빌리프 | 킬레이트화제, 항산화제, 및 산의 조합을 포함하는 안정화된 에피나코나졸-함유 약학 조성물 |
| WO2021054533A2 (ko) * | 2019-09-17 | 2021-03-25 | 주식회사 바이오빌리프 | 산으로서 소르빈산을 포함하는 안정화된 에피나코나졸-함유 약학 조성물 |
| KR20210032662A (ko) * | 2019-09-17 | 2021-03-25 | 주식회사 바이오빌리프 | 킬레이트화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물 |
| KR20210032665A (ko) * | 2019-09-17 | 2021-03-25 | 주식회사 바이오빌리프 | 킬레이트화제 및 항산화제의 조합을 포함하는 안정화된 에피나코나졸-함유 약학 조성물 |
| KR20210032672A (ko) * | 2019-09-17 | 2021-03-25 | 주식회사 바이오빌리프 | 에피나코나졸을 함유하는 안정화된 약학 조성물 |
| JP2021054781A (ja) * | 2019-09-26 | 2021-04-08 | デボン エルエス，リミテッド | 共結晶形エフィナコナゾール、及びその製造方法 |
| WO2021132348A1 (ja) * | 2019-12-24 | 2021-07-01 | 科研製薬株式会社 | エフィナコナゾールを含有する医薬 |
| EP4093396B1 (en) * | 2020-01-22 | 2025-12-10 | Bausch Health Ireland Limited | Topical compositions comprising a macrolide immunosuppressant |
| KR102394599B1 (ko) * | 2020-03-19 | 2022-05-06 | 동아에스티 주식회사 | 에피나코나졸을 함유하는 국소 투여용 약학 조성물 |
| KR102217617B1 (ko) | 2020-08-14 | 2021-02-19 | 비엘엔에이치 주식회사 | 백선의 예방 또는 치료용 약학적 조성물 |
| JP2022547755A (ja) * | 2020-08-14 | 2022-11-16 | ビーエルアンドエイチ カンパニー，リミテッド | 白癬を防止又は処置するための医薬組成物 |
| KR20230096779A (ko) * | 2021-12-23 | 2023-06-30 | 신신제약 주식회사 | 에피코나졸을 함유하는 조갑 진균증 치료용 조성물 |
| US20230346101A1 (en) * | 2022-04-29 | 2023-11-02 | Distinct Dermatology Inc. | Treatment of fungal nail infection |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE41306C (de) | A. STORIE VAN DEN ABEELE in Brügge, Belgien | Tabak-Trockner | ||
| GB865672A (en) * | 1957-06-27 | 1961-04-19 | Boots Pure Drug Co Ltd | Antiseptic therapeutic compositions comprising 2:4-dichlorobenzyl alcohol |
| US3655290A (en) | 1970-10-02 | 1972-04-11 | Griffith & Associates Inc | Applicator instrument |
| US4052513A (en) | 1974-12-13 | 1977-10-04 | Plough, Inc. | Stable topical anesthetic compositions |
| DE3106635A1 (de) | 1981-02-23 | 1982-09-09 | Bayer Ag | Antimykotisches mittel mit hoher wirkstoff-freisetzung in form von stiften |
| US4384589A (en) | 1981-07-27 | 1983-05-24 | American Cyanamid Company | Novel liquid delivery system for toiletries |
| US4912124A (en) | 1984-02-23 | 1990-03-27 | Ortho Pharmaceutical Corporation | Antifungal dermatological solution |
| EP0211555A3 (en) | 1985-08-01 | 1988-06-08 | Dow Corning Corporation | Transparent silicone compositions |
| AU599064B2 (en) | 1985-11-04 | 1990-07-12 | Dermatological Products Of Texas | Film-forming, pharmaceutical vehicles for application of medicaments to nails, pharmaceutical compositions based on those vehicles, and methods of using same |
| US5208257A (en) | 1986-04-21 | 1993-05-04 | Kabara Jon J | Topical antimicrobial pharmaceutical compositions and methods |
| JPS63188609A (ja) | 1987-01-30 | 1988-08-04 | Sansho Seiyaku Kk | 着色を防止した外用剤 |
| FR2673537B1 (fr) | 1991-03-08 | 1993-06-11 | Oreal | Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes. |
| JPH04131463U (ja) * | 1991-05-27 | 1992-12-03 | 貞一 加藤 | ペイント塗布具 |
| US5449715A (en) | 1991-09-17 | 1995-09-12 | Isp Investments Inc. | Colorless, non-toxic, stabilized aqueous solution of a C1-C5 alkyl vinyl ether and maleic acid copolymers |
| ATE138561T1 (de) * | 1992-02-12 | 1996-06-15 | Janssen Cilag S P A | Liposomale itraconazol formulierungen |
| GB9308103D0 (en) | 1993-04-20 | 1993-06-02 | Unilever Plc | Cosmetic composition |
| CN1046278C (zh) | 1993-05-10 | 1999-11-10 | 科研制药株式会社 | 吡咯胺衍生物 |
| US5916545A (en) | 1993-07-28 | 1999-06-29 | Pfizer Inc. | Antifungal nail solution |
| US5391367A (en) | 1993-07-28 | 1995-02-21 | Pfizer Inc. | Antifungal nail solution |
| DE69420419T2 (de) | 1993-09-29 | 1999-12-23 | Alza Corp | Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern |
| US5461068A (en) | 1993-09-29 | 1995-10-24 | Corwood Laboratories, Inc. | Imidazole derivative tincture and method of manufacture |
| JP3608209B2 (ja) | 1993-10-27 | 2005-01-05 | 大正製薬株式会社 | クロタミトン配合外用剤 |
| FR2711898B1 (fr) | 1993-11-05 | 1995-12-29 | Oreal | Pinceau pour appliquer du vernis à ongles, ou un produit analogue. |
| US6040266A (en) | 1994-02-22 | 2000-03-21 | Ultramet | Foam catalyst support for exhaust purification |
| FR2717057B1 (fr) | 1994-03-14 | 1996-04-12 | Oreal | Pinceau de vernis à ongles et ensemble d'application de vernis à ongles muni d'un tel pinceau. |
| US6538039B2 (en) | 1994-04-29 | 2003-03-25 | Laboratoire L. Lafon | Pharmaceutical dosage form for transdermal administration |
| AU3633295A (en) | 1994-09-07 | 1996-03-27 | Johnson & Johnson Consumer Products, Inc. | Retinoid compositions |
| US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
| WO1996030011A1 (en) | 1995-03-30 | 1996-10-03 | Bioplex, L.C. | Topical antimycotic compositions |
| US5549930A (en) | 1995-05-25 | 1996-08-27 | Reysis; Moisei | Dryer and top coat for nail polish |
| US7094422B2 (en) | 1996-02-19 | 2006-08-22 | Acrux Dds Pty Ltd. | Topical delivery of antifungal agents |
| US5696105A (en) | 1996-03-14 | 1997-12-09 | Hackler; Walter A. | Antifungal nail composition |
| US5874069A (en) | 1997-01-24 | 1999-02-23 | Colgate-Palmolive Company | Cosmetic composition containing silicon-modified amides as thickening agents and method of forming same |
| US5728663A (en) * | 1996-07-02 | 1998-03-17 | Johnson & Johnson Consumer Products, Inc. | Clear, colorless soap bar with superior mildness, lathering and discolorization resistence |
| JP4227677B2 (ja) | 1996-12-10 | 2009-02-18 | 杏林製薬株式会社 | 被膜形成性抗真菌剤組成物 |
| CN1252003A (zh) | 1997-03-31 | 2000-05-03 | 强生消费者公司 | 增强药物化合物渗透作用的溶剂系统 |
| US6207142B1 (en) | 1997-04-14 | 2001-03-27 | Janssen Pharmaceutica N.V. | Compositions containing an antifungal and a cationic agent |
| US6165484A (en) | 1997-08-26 | 2000-12-26 | Wake Forest University | EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections |
| JP3420044B2 (ja) * | 1997-11-12 | 2003-06-23 | 興和株式会社 | 液塗布容器 |
| US6197305B1 (en) | 1998-01-05 | 2001-03-06 | Farmo-Nat Ltd. | Anti-fungal compositions with prolonged activity |
| KR100269323B1 (ko) | 1998-01-16 | 2000-10-16 | 윤종용 | 반도체장치의백금막식각방법 |
| US6022551A (en) | 1998-01-20 | 2000-02-08 | Ethicon, Inc. | Antimicrobial composition |
| US5997893A (en) | 1998-01-20 | 1999-12-07 | Ethicon, Inc. | Alcohol based anti-microbial compositions with cosmetic appearance |
| US20020022660A1 (en) | 1998-01-20 | 2002-02-21 | Hanuman B. Jampani | Deep penetrating antimicrobial compositions |
| US5972358A (en) | 1998-01-20 | 1999-10-26 | Ethicon, Inc. | Low tack lotion, gels and creams |
| US6231875B1 (en) | 1998-03-31 | 2001-05-15 | Johnson & Johnson Consumer Companies, Inc. | Acidified composition for topical treatment of nail and skin conditions |
| ES2190204T3 (es) | 1998-04-03 | 2003-07-16 | Colgate Palmolive Co | Composicion cosmetica baja en residuos. |
| US6306375B1 (en) | 1998-05-01 | 2001-10-23 | The Procter & Gamble Company | Long wear nail polish having defined surface properties |
| US20030007939A1 (en) | 1998-07-31 | 2003-01-09 | Howard Murad | Pharmaceutical compositions and methods for managing dermatological conditions |
| US6264927B1 (en) | 1998-08-27 | 2001-07-24 | Elmer P. Monahan | Topical solution and method for the treatment of nail fungus |
| DE59911740D1 (de) | 1998-09-10 | 2005-04-14 | Bioequal Ag Muttenz | Topisch anwendbare mittel gegen nagelpilzerkrankungen |
| US7026308B1 (en) | 1999-06-25 | 2006-04-11 | The Procter & Gamble Company | Topical anti-microbial compositions |
| EP1205559B1 (en) | 1999-07-28 | 2009-06-24 | Kaken Pharmaceutical Co., Ltd. | Method for detecting pathogenic microorganisms and antimicrobial agents, method for evaluating the drug effect of antimicrobial agents, and antimicrobial agents |
| WO2001008529A2 (en) | 1999-07-30 | 2001-02-08 | The Procter & Gamble Company | Method for treating and preventing finger disorders |
| US6287611B1 (en) * | 2000-02-01 | 2001-09-11 | Stokely-Van Camp, Inc. | Beverage having L-ascorbic acid with stability of color and clarity |
| JP4780429B2 (ja) | 2000-04-07 | 2011-09-28 | 大正製薬株式会社 | ミノキシジル含有製剤 |
| JP4726279B2 (ja) * | 2000-06-30 | 2011-07-20 | 三菱鉛筆株式会社 | 液体塗布具 |
| US6433073B1 (en) | 2000-07-27 | 2002-08-13 | 3M Innovative Properties Company | Polyurethane dispersion in alcohol-water system |
| JP3680081B2 (ja) * | 2000-11-16 | 2005-08-10 | 独立行政法人農業生物資源研究所 | キレート剤を含むヘリコバクター・ピロリ菌用抗菌剤 |
| US6676953B2 (en) | 2001-01-26 | 2004-01-13 | Don L. Hexamer | Antifungal composition and method for human nails |
| US6585963B1 (en) | 2001-02-15 | 2003-07-01 | Watson Pharmaceuticals, Inc. | Nail compositions and methods of administering same |
| US20030039621A1 (en) | 2001-04-10 | 2003-02-27 | L'oreal | Two-coat make-up product, its use and a kit containing the make-up product |
| US6664292B2 (en) | 2001-06-04 | 2003-12-16 | Mark H. Bogart | Methods for the treatment of nail fungus and other microbial and mycotic conditions and compositions useful therefor |
| US6821508B2 (en) * | 2001-06-27 | 2004-11-23 | Rutgers, The State University | Composition and method for topical nail treatment |
| WO2003013447A2 (en) | 2001-08-07 | 2003-02-20 | Dow Corning Corporation | Hair and skin care compositions containing siloxane-based polyamide copolymers |
| US7043791B2 (en) | 2001-10-16 | 2006-05-16 | Aubex Corporation | Applicator |
| US6846837B2 (en) | 2002-06-21 | 2005-01-25 | Howard I. Maibach | Topical administration of basic antifungal compositions to treat fungal infections of the nails |
| JP2004083439A (ja) | 2002-08-23 | 2004-03-18 | Ss Pharmaceut Co Ltd | 爪用抗真菌外用剤 |
| KR20050042488A (ko) | 2002-09-05 | 2005-05-09 | 갈데르마 소시에떼아노님 | 조갑 적용용 용액 |
| US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
| US20040180025A1 (en) | 2003-03-12 | 2004-09-16 | New Life Resources, Llc | Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations |
| US20050142094A1 (en) | 2003-03-12 | 2005-06-30 | Manoj Kumar | Use of repeat sequence protein polymers in personal care compositions |
| DE602004021253D1 (de) | 2003-03-21 | 2009-07-09 | Nexmed Holdings Inc | Antimykotischer nagellack und anwendungsverfahren |
| FR2856301B1 (fr) | 2003-06-23 | 2007-08-03 | Galderma Res & Dev | Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile |
| GB2407496A (en) | 2003-10-27 | 2005-05-04 | Dow Corning | Method for forming a polysiloxane film on a biological surface |
| PT1686972E (pt) | 2003-11-21 | 2008-04-23 | Galderma Res & Dev | Composição pulverizável para a administração de derivados da itamina d |
| FR2862540B1 (fr) | 2003-11-21 | 2007-03-30 | Galderma Res & Dev | Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile |
| WO2005065668A2 (en) | 2003-12-29 | 2005-07-21 | Qlt Usa, Inc. | Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders |
| US7622844B1 (en) | 2003-12-30 | 2009-11-24 | Hipercon, Llc | Metal fiber brush interface conditioning |
| US20050176650A1 (en) | 2004-02-09 | 2005-08-11 | Xanodyne Pharmacal, Inc. | Stable parenteral formulation of levomepromazine and a method for stabilizing said formulation |
| FR2871697B1 (fr) | 2004-06-17 | 2007-06-29 | Galderma Sa | Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile |
| US20060008538A1 (en) | 2004-07-07 | 2006-01-12 | Wu Jeffrey M | Methods of treating the skin |
| US20070082039A1 (en) | 2004-10-18 | 2007-04-12 | Jones Gerald S Jr | Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids |
| US20060110415A1 (en) | 2004-11-22 | 2006-05-25 | Bioderm Research | Topical Delivery System for Cosmetic and Pharmaceutical Agents |
| US20060165747A1 (en) | 2005-01-24 | 2006-07-27 | David Rolf | Antifungal composition, method and kit for topically treating onychomycosis |
| US7767657B2 (en) | 2005-02-16 | 2010-08-03 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| SI2343304T1 (sl) | 2005-02-16 | 2015-08-31 | Anacor Pharmaceuticals, Inc. | Biocidne boroftalidne spojine |
| US20060280706A1 (en) | 2005-05-25 | 2006-12-14 | L'oreal | Rinse-off cosmetic composition containing interference particles |
| US20070071705A1 (en) | 2005-09-29 | 2007-03-29 | De Oliveira Monica A M | Topical anti-microbial compositions |
| WO2007070643A2 (en) | 2005-12-14 | 2007-06-21 | Zars, Inc. | Compositions and methods for treating dermatological conditions |
| US20070142478A1 (en) | 2005-12-21 | 2007-06-21 | Erning Xia | Combination antimicrobial composition and method of use |
| CN101460060A (zh) | 2006-03-01 | 2009-06-17 | 特莱斯特拉塔公司 | 局部治疗焦油响应性皮肤病用的组合物和方法 |
| US20070207107A1 (en) | 2006-03-03 | 2007-09-06 | Gareth Winckle | Silicone based emulsions for topical drug delivery |
| CA2645073A1 (en) | 2006-03-08 | 2007-09-13 | Nuviance, Inc. | Transdermal drug delivery compositions and topical compositions for application on the skin |
| AU2006339841B2 (en) | 2006-03-08 | 2012-08-30 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
| US7950865B2 (en) | 2006-03-21 | 2011-05-31 | L'oreal | Packaging and applicator device |
| WO2007123800A2 (en) | 2006-04-03 | 2007-11-01 | Nutramax Laboratories, Inc. | Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them |
| WO2008001200A2 (en) | 2006-06-29 | 2008-01-03 | Antares Pharma Ipl Ag | Transdermal composition having enhanced color stability |
| MXPA06008988A (es) | 2006-08-08 | 2008-02-07 | Fernando Ahumada Ayala | Preparaciones topicas antiacne que contienen retinoide (tazaroteno o adapaleno), antibiotico (fosfato de clindamicina) y/o queratolitico (peroxido de bonzoilo en microesponjas). |
| US20080317684A1 (en) | 2006-09-06 | 2008-12-25 | Isw Group, Inc. | Topical Compositions |
| EP2116243B1 (en) * | 2006-12-28 | 2010-09-29 | Kaken Pharmaceutical Co., Ltd. | Gel composition for treating mycosis |
| WO2008124131A1 (en) | 2007-04-05 | 2008-10-16 | The John Hopkins University | Antifungal agents as neuroprotectants |
| US20090175810A1 (en) | 2008-01-03 | 2009-07-09 | Gareth Winckle | Compositions and methods for treating diseases of the nail |
| JP2009263346A (ja) | 2008-03-31 | 2009-11-12 | Kose Corp | カイネチンを含有する乳化型化粧料 |
| EP2687846B1 (en) * | 2008-06-13 | 2016-10-12 | Alt Bioscience, Llc. | Device for rapid determination of disease-associated thiol compounds |
| JP2012516889A (ja) | 2009-02-05 | 2012-07-26 | ターゲッティド デリバリー テクノロジーズ リミテッド | 微生物因子の増殖及び生存能力を低下させる方法 |
| WO2010093992A1 (en) * | 2009-02-13 | 2010-08-19 | Topica Pharmaceuticals, Inc | Anti-fungal formulation |
| FR2942716B1 (fr) | 2009-03-06 | 2011-04-15 | Galderma Res & Dev | Methode de solubilisation d'agent antifongique et compositions a haute concentration en agent antifongique applicables sur l'ongle |
| WO2011008770A2 (en) | 2009-07-14 | 2011-01-20 | Biogen Idec Ma Inc. | Methods for inhibiting yellow color and peroxide formation in a composition |
| WO2011064558A2 (en) | 2009-11-30 | 2011-06-03 | Cipla Limited | Pharmaceutical composition |
| FR2954164B1 (fr) | 2009-12-18 | 2012-03-16 | Galderma Pharma Sa | Composition antifongique destinee a etre appliquee sur l'ongle perfore |
| BR112012029418A2 (pt) | 2010-05-20 | 2017-02-21 | Hyun Jung Chung | composição de preparação para a pele para uso externo com excelentes efeitos antibacterianos e antifúngicos |
| BR112012033077B8 (pt) | 2010-06-29 | 2023-04-25 | Merck Sharp & Dohme | Composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit |
| US8039494B1 (en) | 2010-07-08 | 2011-10-18 | Dow Pharmaceutical Sciences, Inc. | Compositions and methods for treating diseases of the nail |
| DK2612859T3 (en) | 2010-08-31 | 2015-10-19 | Kaken Pharma Co Ltd | PROCEDURE FOR PREPARING 1-TRIAZOL-2-BUTANOL DERIVATE. |
| JP6005344B2 (ja) | 2011-07-05 | 2016-10-12 | 科研製薬株式会社 | 爪白癬薬用塗布具 |
| KR101633479B1 (ko) | 2012-02-28 | 2016-07-08 | 사이덱스 파마슈티칼스, 인크. | 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법 |
| US9662394B2 (en) * | 2013-10-03 | 2017-05-30 | Dow Pharmaceutical Sciences, Inc. | Stabilized efinaconazole compositions |
| CN112999223A (zh) * | 2013-11-22 | 2021-06-22 | 博世健康爱尔兰有限公司 | 抗感染的方法、组合物和装置 |
-
2014
- 2014-11-24 CN CN202110215564.7A patent/CN112999223A/zh active Pending
- 2014-11-24 US US14/552,307 patent/US10245257B2/en active Active
- 2014-11-24 KR KR1020167016606A patent/KR20160087898A/ko not_active Ceased
- 2014-11-24 JP JP2016554823A patent/JP6611014B2/ja active Active
- 2014-11-24 CA CA2931144A patent/CA2931144C/en active Active
- 2014-11-24 CN CN201480071463.5A patent/CN105848719A/zh active Pending
- 2014-11-24 CA CA3052643A patent/CA3052643A1/en not_active Abandoned
- 2014-11-24 KR KR1020237003019A patent/KR102612453B1/ko active Active
- 2014-11-24 EP EP14864821.5A patent/EP3071295A4/en active Pending
- 2014-11-24 WO PCT/US2014/067184 patent/WO2015077729A2/en not_active Ceased
-
2019
- 2019-03-14 US US16/353,849 patent/US10828293B2/en active Active
- 2019-08-23 JP JP2019152482A patent/JP2020002153A/ja active Pending
-
2020
- 2020-10-05 US US17/062,973 patent/US11654139B2/en active Active
-
2023
- 2023-04-12 US US18/299,664 patent/US20230293508A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160087898A (ko) | 2016-07-22 |
| WO2015077729A3 (en) | 2015-11-12 |
| CA3052643A1 (en) | 2015-05-28 |
| EP3071295A4 (en) | 2017-05-31 |
| US11654139B2 (en) | 2023-05-23 |
| WO2015077729A2 (en) | 2015-05-28 |
| US20150148378A1 (en) | 2015-05-28 |
| JP6611014B2 (ja) | 2019-11-27 |
| KR20230019228A (ko) | 2023-02-07 |
| US20210023069A1 (en) | 2021-01-28 |
| EP3071295A2 (en) | 2016-09-28 |
| US10828293B2 (en) | 2020-11-10 |
| CN105848719A (zh) | 2016-08-10 |
| US10245257B2 (en) | 2019-04-02 |
| CN112999223A (zh) | 2021-06-22 |
| CA2931144A1 (en) | 2015-05-28 |
| KR102612453B1 (ko) | 2023-12-08 |
| JP2020002153A (ja) | 2020-01-09 |
| US20230293508A1 (en) | 2023-09-21 |
| JP2017500374A (ja) | 2017-01-05 |
| US20190209543A1 (en) | 2019-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230293508A1 (en) | Anti-infective methods, compositions, and devices | |
| US5230897A (en) | Transdermal pentamidine | |
| EP1214064B1 (en) | Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores | |
| US8883767B2 (en) | Low ether compositions and delivery apparatus | |
| EP2373305B1 (en) | Transdermal pharmaceutical compositions comprising a serm | |
| JP5667052B2 (ja) | ダナゾールを含む経真皮医薬組成物 | |
| CN101262848B (zh) | 抗真菌组合物 | |
| US20220118236A1 (en) | Roll-on applicators and methods for treating dermal conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190207 |